1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
The effectiveness of 1alpha-hydroxycholecalciferol [1alpha-OH)D3] in healing uremic bone disease was investigated in 10 uremic patients on maintenance dialysis. Seven patients received 1alpha-(OH)D3, 2 microgram/day, for six months, and three patients served as a control group. Bone density was determined from X-rays of the second phalanx of the second digit. The apparent intestinal calcium absorption improved on treatment with 1alpha-(OH)D3, serum calcium levels and bone density significantly increased, and a significant decrease in serum alkaline phosphatase activity was observed. In one patient, reversal of uremic myopathy occurred after 17 days of 1alpha-(OH)D3 therapy.
D015502:Absorptiometry, Photon; D000469:Alkaline Phosphatase / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006996:Hypocalcemia / Q000097:blood / Q000188:drug therapy; D007413:Intestinal Mucosa / Q000378:metabolism; D014511:Uremia / Q000188:drug therapy
D006887:Hydroxycholecalciferols; D000469:Alkaline Phosphatase